Travere Therapeutics Inc. (TVTX)
NASDAQ: TVTX
· Real-Time Price · USD
15.39
-0.45 (-2.84%)
At close: May 27, 2025, 3:32 PM
Travere Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
| Royalty Revenue | 600K | 17.7M |
| Royalty Revenue Growth | -96.61% | n/a |
| License Revenue | 6.47M | n/a |
| License Revenue Growth | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 72.84M | 69.5M | 65.62M | 54.43M | 64.22M | 52.73M | 67.8M | 74.04M | 72.25M | 62.92M | 57.52M | 52.98M | 46.79M | 42.08M | 36.06M | 34.97M | 36.78M | 35.74M | 31.95M | 34.97M | 33.14M | 27.53M | 29.78M | 38.97M | 32.67M | 25.95M | 26.11M | 25.1M | 26.47M | 27.27M | 24.85M | 28.84M | 23.11M | 26.63M | 29.06M | 23.2M | 19.13M | 22.69M | 22.31M | 19.69M | 14.86M |
| Selling, General, and Administrative Revenue Growth | +4.80% | +5.92% | +20.55% | -15.25% | +21.79% | -22.22% | -8.42% | +2.48% | +14.82% | +9.39% | +8.57% | +13.23% | +11.20% | +16.66% | +3.15% | -4.93% | +2.91% | +11.85% | -8.64% | +5.53% | +20.36% | -7.54% | -23.58% | +19.29% | +25.87% | -0.58% | +4.01% | -5.17% | -2.96% | +9.75% | -13.81% | +24.75% | -13.18% | -8.38% | +25.23% | +21.33% | -15.70% | +1.69% | +13.28% | +32.56% | n/a |
| Research and Development Revenue | 46.89M | 62.07M | 51.68M | 54.33M | 114.63M | 58.75M | 60.59M | 69.41M | 59.91M | 60.23M | 59.26M | 59.68M | 56.61M | 62.17M | 48.41M | 51.81M | 47.95M | 38.38M | 32.35M | 30.79M | 30.25M | 36.37M | 33.22M | 37.93M | 33.44M | 32M | 32.45M | 34.46M | 24.64M | 19.58M | 19.61M | 19.48M | 20.86M | 20.08M | 18.43M | 17.68M | 14.67M | 15.45M | 14.06M | 10.56M | 10.35M |
| Research and Development Revenue Growth | -24.45% | +20.10% | -4.88% | -52.60% | +95.11% | -3.04% | -12.71% | +15.85% | -0.53% | +1.65% | -0.71% | +5.42% | -8.94% | +28.43% | -6.56% | +8.05% | +24.91% | +18.66% | +5.06% | +1.79% | -16.82% | +9.47% | -12.43% | +13.43% | +4.53% | -1.40% | -5.84% | +39.88% | +25.85% | -0.17% | +0.66% | -6.61% | +3.89% | +8.95% | +4.26% | +20.47% | -5.05% | +9.87% | +33.14% | +2.09% | n/a |